One way that CNETS Canada honours those individuals who have made an outstanding commitment and contribution to the NET cancer patient community is through our annual Maureen Coleman award. Maureen [...]
Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors (PET/Ga68) Phase-II, prospective, open label, no control group to assess the safety of 68Ga-DOTA-TATE [...]
“Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs” – a collaborative effort between the International Neuroendocrine Cancer Alliance (INCA) and [...]
After review of the results of our recently conducted patient support survey and based on input from our local communities and our local Support Group Leaders, we are implementing the [...]
Over the last several years CNETS Canada has worked hard to continuously improve our website and the information contained in it to ensure that it is highly functional and as [...]
A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment With Individualized Dosimetry in Patients With 68Ga-DOTATATE Identified Somatostatin Receptor Positive Neuroendocrine Tumors Not yet [...]
The Pan-Canadian Oncology Drug Review (pCODR) will be considering an application for the drug Everolimus (Afinitor) indicated for Gastrointestinal and Lung Neuroendocrine (NET) Tumours. Everolimus is a cancer medicine that [...]
We are pleased to announce that this week, we are officially launching our 177Lu-octreotate PRRT clinical trial at CHU de Québec, which is called: Personalized Peptide Receptor Radionuclide Therapy of [...]
CNETS Canada's President, Jackie Herman is quoted in Maclean’s Magazine Digestive Health Supplement
This past March CNETS Canada held its first Scientific and Medical Advisory Board (SMAB) meeting in Toronto. The SMAB is composed of prominent Canadian physicians and scientists passionate about the [...]